Frontline zanidatamab plus docetaxel yields antitumor activity, safety in advanced HER2+ breast cancer
Last Updated: Friday, July 17, 2026
According to phase 1b/2 updated data presented during the 2023 ASCO Breakthrough Meeting, first-line treatment with the novel HER2-targeted bispecific antibody zanidatamab plus docetaxel among patients with unresectable, locally advanced, recurrent or metastatic HER2-positive breast cancer demonstrated efficacy with a manageable safety profile.